Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Trial Profile

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Vorinostat (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 02 Aug 2016 Number of treatment arms changed from 1 to 2.
    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top